NA-931

DRUG2 trials

Sponsors

Biomed Industries, Inc.

Conditions

Obesity and OverweightOverweight or ObesityType 2 Diabetes

Phase 1

Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus

CompletedNCT06615700

Biomed Industries, Inc.Overweight or Obesity, Type 2 Diabetes

Start: 2024-05-06End: 2024-09-20Updated: 2024-09-27

Phase 2

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Not yet recruitingNCT06732245

Biomed Industries, Inc.Obesity and Overweight

Start: 2026-08-15End: 2027-12-15Target: 224Updated: 2026-03-27

Related Papers

Neuro‐Metabolic Association in Alzheimer’s Disease and Obesity: Clinical Evaluation of NA‐831 and NA‐931

Alzheimer s & Dementia2025-12-01

143-OR: NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss

Diabetes2025-06-13